Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome
A legfontosabb adatok
- Ki végzi
- University of Arizona
- Hol
- Tucson (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Fut, nem toboroz
- Fázis
- 2. fázis
- Résztvevők
- 36 fő, tervezett
- Kezdés
- 2023. szept. 29.
- Befejezés
- 2026. jún.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Atomoxetine and Oxybutynin (ato-oxy)
- A regiszteradat frissítve
- 2026. április 7.
Ki vehet részt
- Életkor
- 6 év – 17 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female participants between 6 to 17 years of age, inclusive, at the Screening Visit
- Known diagnosis of Down syndrome (trisomy 21, but not translocation or mosaicism)
Ki nem vehet részt
- Currently using and adherent to positive airway pressure therapy (>4 hours per night for 70% of nights in the past 30 days based on device download or parent report)
- Monoamine oxidase inhibitor use
- Seizure disorder
- Congenital heart disease and not cleared to participate by the patient's cardiologist
- History of current, untreated depression
- History of liver disease
- Prematurity < 32 weeks estimated gestational age
- Presence of central sleep apnea on polysomnography (central AHI ≥ 5)
- Urinary retention
- Untreated or inadequately treated hypothyroidism
- Significant traumatic brain injury
- 3+ or greater tonsillar hypertrophy
- Positive urine pregnancy test
- Hypoxemia independent of respiratory events on baseline polysomnography (≥5 minutes with oxygen saturation <90%)
- Presence of central sleep apnea on baseline polysomnography (central AHI ≥ 5)
- Absence of OSA defined as total AHI <5 on baseline polysomnography
Helyszínek itt: Egyesült Államok
- University of ArizonaTucson, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is an open-label study of the combination of atomoxetine and oxybutynin (ato-oxy) in children with Down syndrome and obstructive sleep apnea (OSA) documented by polysomnography (PSG). Participants will receive ato-oxy for 6 months. Ato-oxy dose will be 5 mg oxybutynin and 0.5mg/kg/day (max 40 mg) atomoxetine. Dosing of the study treatment will occur approximately 30 minutes prior to bedtime. Participants who withdraw from the study will not be replaced.
A teljes eredeti leírásKevesebb
Study participants will undergo eligibility screening that will include an initial screening to determine whether non- PSG enrollment criteria are met, followed by a 1 night in-lab PSG and health-related quality of life (HRQOL) and cognitive assessment for participants who qualify based on non-PSG criteria. For participants who are eligible and enroll in the study, the screening PSG night will serve as the baseline measure for apnea hypopnea index (AHI) and other PSG endpoints. On the final night of dosing for ato-oxy participants will return for inpatient PSG and health-related quality of life assessment and cognitive assessment. The primary efficacy endpoint is the change in obstructive AHI from baseline.
A vizsgálat csoportja
- Ato-oxyA vizsgált kezelés
0.5 mg/kg (max 40 mg) atomoxetine and 5 mg oxybutynin
Kezelés: Atomoxetine and Oxybutynin (ato-oxy)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2026. április 7.